Dear Editor,

We read with interest the study by Vrsalovic et al. which examined the prognostic value of high-sensitive (hs) troponin in terms of mortality in patients with COVID-19.[@bib0001] In patients with COVID-19, cardiac injury is not uncommon and may be attributed to ischemic and non-ischemic causes, including myocardial infarction, coronary microvascular ischemia, cytokine storm, viral myocarditis, stress cardiomyopathy, tachyarrhythmia, or pulmonary embolism.[@bib0002]

Based on the frequency and non-specific nature of abnormal troponin results in COVID-19 patients, the American College of Cardiology, advised clinicians to *"measure troponin only if the diagnosis of acute myocardial infarction is being considered on clinical grounds"*.[@bib0003] It has been stressed, however, that troponin is not a test solely for myocardial infarction, but it might also be used as a crucial diagnostic and prognostic tool for risk stratification in COVID-19 patients.[@bib0001] ^,^ [@bib0002]

Vrsalovic et al. meta-analyzed 3 studies (*n* = 803), all conducted in China, showing that cardiac injury, defined by an increased hs-troponin value, is associated with an adjusted pooled hazard ratio (HR) of 2.5 (95% confidence intervals \[CI\] 1.5, 4.1) for death.[@bib0001] This analysis is important because only studies reporting adjusted HR were included. However, some methodological issues should be considered: (i) two of these studies in this meta-analysis recruited subjects from the same department/hospital within similar time periods, which cannot exclude participants' overlapping,[@bib0004] ^,^ [@bib0005] (ii) one of the studies has not been subjected to peer-review,[@bib0006] (iii) the evidence appears to be preliminary and emerging.

We performed an updated systematic review using the following algorithm search strategy in PubMed: ("coronavirus 2019" OR "2019-nCoV" OR "SARS-CoV-2" OR "COVID-19") AND (death OR prognos\* OR mortality OR outcome) AND (troponin OR "cardiac injury") until May 30, 2020. Hand search for eligible articles through the reference list of relevant articles was also performed. Inclusion criteria included full-text articles in English that reported adjusted HR for cardiac injury, defined by increased hs-troponin values, in terms of mortality among patients with COVID-19. In case of studies conducted in the same hospital and the same period, we attempted to clarify overlapping by communicating with the corresponding authors. As the latter was unsuccessful, the study with the largest sample was considered for inclusion. HR and 95% CI values were logarithmically transformed and standard errors were calculated from these values and used in the analysis. Heterogeneity was assessed by the Cochran Q statistic. A p value \<0.1 was considered to indicate significant heterogeneity and random-effects model of analysis was used. Meta-analysis was performed using the Stata/ SE 11.2 (Texas) software.

Among 94 articles initially identified, 3 studies fulfilled the inclusion criteria ([Table 1](#tbl0001){ref-type="table"} ).[@bib0007], [@bib0008], [@bib0009] There was heterogeneity among these studies in defining cardiac injury ([Table 1](#tbl0001){ref-type="table"}). In one study HR were given for 2 groups of increased troponin versus reference and these were pooled to a study-unique HR. A meta-analysis of these studies (*n* = 3956) revealed a pooled adjusted HR 2.3 (95% CI 1.3, 4.1) ([Fig. 1](#fig0001){ref-type="fig"} ). It is important to mention that adjustment in the models of these studies was performed for several factors, including comorbidities and/or vital signs and laboratory results.Table 1Main characteristics and key results of 3 studies included in meta-analysis.Table 1StudyCity, CountryNAge (ys), median (IQR)Cardiac injury definitionAdjusted hazard ratio for mortality (95% CI)Petrilli et al.[@bib0007]NY, USA273763 (51--74)Admission troponin I1.6 (1.3, 1.9)[\*](#tb1fn1){ref-type="table-fn"}\>0.1 ng/mLShi et al.[@bib0008]Wuhan, China67163 (50--72)Admission troponin I4.6 (1.3, 16.3)\>0.026 ng/mLLi et al.[@bib0009]Wuhan, China54860 (48--69)Troponin I2.9 (1.8, 4.8)\>0.0156 ng/mL[^1]Fig. 1Forest plot of adjusted hazard ratios for mortality associated with cardiac injury in patients with COVID-19.Fig. 1

Evidence regarding the natural course of the COVID-19 is rapidly evolving, calling for immediate translation into clinical practice during the pandemic. The available data from China and US are preliminary but important. Meta-analysis of the current evidence suggests that cardiac injury defined by elevated hs-troponin has independent adverse prognostic value in COVID-19. Further research is needed to confirm the independent prognostic value of hs-troponin and investigate the pathogenetic mechanisms of cardiac injury in COVID-19 and its impact on mortality. Whether an increased hs-troponin is due to direct cardiac effects of the SARS-CoV-2, or indirect injury induced by the cytokine storm remains unclear. However, physicians should be aware that an increased value of hs-troponin might be useful in risk stratification of COVID-19 patients and should therefore be included in routine assessment.
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[^1]: pooled estimate.
